The latest research,explained.
New treatments and completed trials across every condition — what was tested, what was found, and what it means for patients.
Podcast
New · This Week in Clinical Trials
This Week in Clinical Trials — May 4, 2026
4 min · May 4, 2026 · Episode 1
What the RUBY Trial Found — Gene Editing for Sickle Cell Disease
The RUBY trial tested reni-cel, a one-time gene editing treatment for patients with severe sickle cell disease who experience frequent painful crises. Researchers modified each patient's own stem cells to reactivate fetal hemoglobin — preventing cells from taking the sickle shape that causes blockages and organ damage.
What this means for patients
Reni-cel is not yet FDA-approved — this was a safety and early efficacy trial. Two other gene therapies (Casgevy and Lyfgenia) are already approved and may be available through your treatment center. Ask your hematologist about eligibility for approved gene therapies, and ask about any open gene editing trials.
What the TEMPO-3 Trial Found — Tavapadon Added to Levodopa for Parkinson's
TEMPO-3 tested tavapadon — a once-daily selective dopamine pill — added to levodopa in 507 people with Parkinson's and motor fluctuations. Tavapadon added about 1.1 hours of good on-time per day.
Read →What the OCULUS Trial Found — Holding GLP-1 Drugs Before Upper Endoscopy
OCULUS tested whether holding one weekly or daily dose of a GLP-1 drug (like Ozempic or Mounjaro) before upper endoscopy reduces stomach contents that complicate sedation. The trial was stopped early — 25% who continued had retained food vs. 3% who held the dose.
Read →What the LAURA Trial Found — Osimertinib After Chemoradiation for Stage III Lung Cancer
A daily targeted pill reduced disease progression risk by 84% in unresectable Stage III EGFR-mutated non-small cell lung cancer after chemoradiation — a population with few good options after completing standard treatment.
Read →What the STRENGTH Trial Found — Spinal Onasemnogene Abeparvovec for Older SMA Patients
STRENGTH tested intrathecal onasemnogene abeparvovec — a spinal-fluid version of Zolgensma — in 27 children and teens with SMA who had stopped nusinersen or risdiplam. The 52-week safety profile matched what was seen in younger, untreated patients.
Read →What the monarchE Trial Found — Abemaciclib After Surgery for HR+ Breast Cancer
Adding abemaciclib to hormone therapy after surgery cut the risk of cancer returning by 35% in high-risk hormone receptor-positive breast cancer patients — a meaningful improvement over hormone therapy alone.
Read →What Researchers Found Testing Multi-Antigen T Cell Therapy for Pancreatic Cancer
This 37-patient trial gave a personalized T cell therapy targeting five tumor proteins to people with advanced pancreatic cancer. In patients responding to chemotherapy, the disease control rate was 85%; two of nine patients with resectable disease were still cancer-free 5+ years later.
Read →Condition guides
Start with the bigger picture
Breast Cancer
3,601 activeBreast cancer is not one disease — it splits into hormone-receptor-positive, HER2-positive, and triple-negative subtypes that respond to very different treatments.
Read the guide →Lung Cancer
3,293 activeLung cancer treatment has changed more in the past ten years than in the previous fifty.
Read the guide →Cervical Cancer
3,249 activeCervical cancer is caused mainly by persistent HPV infection, which means prevention through vaccination is now a real possibility for future generations.
Read the guide →Head And Neck Cancer
2,537 activeHead and neck cancers — tumors of the mouth, throat, larynx, and salivary glands — are increasingly linked to HPV infection in younger patients, which changes how they respond to treatment.
Read the guide →Lymphoma
2,536 activeLymphoma covers more than 70 different cancers of the immune system, and treatment varies enormously by type — some grow slowly and need only watchful waiting, while aggressive forms can be cured with chemotherapy.
Read the guide →Coronary Artery Disease
2,142 activeCoronary artery disease develops when plaques build up inside the arteries that supply the heart, narrowing blood flow and raising the risk of heart attack.
Read the guide →